The knowledge that GATA2 mutation is a constitutive risk factor for MDS/AML begs an important question of whether acquired GATA2 mutation is among the key leukaemia-initiating events in sporadic MDS/AML (Table IV). The gene discussed is GATA2; the disease is leukemia.